Elsevier

Vaccine

Volume 33, Issue 42, 13 October 2015, Pages 5520-5531
Vaccine

Review
Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe

https://doi.org/10.1016/j.vaccine.2015.08.020Get rights and content
Under a Creative Commons license
open access

Abstract

Rift Valley fever virus (RVFV) is a mosquito-borne virus, and is the causative agent of Rift Valley fever (RVF), a zoonotic disease characterised by an increased incidence of abortion or foetal malformation in ruminants. Infection in humans can also lead to clinical manifestations that in severe cases cause encephalitis or haemorrhagic fever. The virus is endemic throughout much of the African continent. However, the emergence of RVFV in the Middle East, northern Egypt and the Comoros Archipelago has highlighted that the geographical range of RVFV may be increasing, and has led to the concern that an incursion into Europe may occur. At present, there is a limited range of veterinary vaccines available for use in endemic areas, and there is no licensed human vaccine. In this review, the methods available for diagnosis of RVFV infection, the current status of vaccine development and possible implications for RVFV emergence in Europe, are discussed.

Keywords

Rift valley fever
Virus
Vaccine

Cited by (0)

This review is dedicated to Professor Richard M. Elliott (1954-2015) for his friendship, support and outstanding contributions to virology, especially in the field of bunyavirus research.